The interaction between endothelin-1 and C-reactive protein and their impact on long-term prognosis after percutaneous coronary interventions

Archives of Medical Science

Volumn 5, Issue 1, 2009, Pages 38-44

  Catakoglu, Alp Burak ^a,b   Aytekin, Vedat ^a   Demiroglu, Cemsid ^a   Aytekin, Saide ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

C reactive protein; Endothelin 1; MACE; Percutaneous coronary intervention

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DEATH; FEMALE; HEART HEMODYNAMICS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REOPERATION; STENT;

EID: 65549128164     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
2. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.
3. Brunetti ND, Troccoli R, Correale M, Pellegrino Pl, Di Biase M. C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol 2006; 109: 248-56.
4. Mockel M, Heller G Jr, Müller C, et al. C-reactive protein as an independent marker of prognosis in acute coronary syndrome: comparison with troponin T [German]. Z Kardiol 2000; 89: 658-66.
5. Dashwood MR, Debnam ES, Bagnall J, Thompson CS. Autoradiographic localisation of opiate receptors in rat small intestine. Eur J Pharmacol 1985; 107: 267-9.
6. Wieczorek I, Haynes WG, Webb DJ, Ludlam CA, Fox KA. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 1994; 72: 436-41.
7. Yazici M, Demircan S, Durna K, Sahin M. The relation between endothelin-1 levels and myocardial injury in chronic ischemic heart failure. Heart Vessels 2005; 20: 95-9.
8. Aytekin S, Catakoglu AB, Aytekin V, Kocazeybek B, Demiroglu IC, Demiroglu C. C-reactive protein as a pre-procedural predictor of early and late outcomes of percutaneous coronary interventions. Int J Angiol 2003; 12: 229-33.
9. Hahn JY, Kim HS, Koo BK, et al. One month follow-up C-reactive protein may be a useful predictor of angiographic restenosis and long-term clinical outcomes after bare metal stent implantation. Int J Cardiol 2006; 109: 267-9.
10. Gach O, Legrand V, Biessaux Y, Chapelle JP, Vanbelle S, Pierard LA. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007; 99: 31-5.
11. Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M. A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 2004; 173: 285-90.
12. Markuszewski L, Rysz J, Makowski M, Debska A, Pietruszynski R. C-reactive protein as a predictor of major adverse cardiac events (MACE) after percutaneous coronary intervention? Arch Med Sci 2005; 3: 152-6.
13. Wainstein MV, Goncalves SC, Zago AJ, et al. Plasma endothelin-1 levels after coronary stenting in humans. Am J Cardiol 2003; 92: 1211-4.
14. Luo Y, Jiang D, Wen D, Yang J, Li L. Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin. Heart Vessels 2004; 19: 257-62.
15. Kavsak PA, MacRae AR, Newman AM, et al. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem 2007; 40: 326-9.
16. Zairis MN, Adamopoulou EN, Manousakis SJ, et al.; Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007; 194: 397-402.
17. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-21.
18. Saleh N, Tornvall P. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis 2007; 195: 374-8.
19. Zhou YF, Csako G, Grayston JT, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 1999; 84: 595-8.
20. Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res 2001; 24: 163-76.
21. Serrano CV Jr, Ramires JA, Venturinelli M, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997; 29: 1276-83.
22. Du Clos TW. Function of C-reactive protein. Ann Med 2000; 32: 274-8.
23. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101: 1785-91.
24. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001; 104: 974-5.
25. Douglas SA, Louden C, Vickery-Clark LM, et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res 1994; 75: 190-7.
26. Hedman A, Larsson PT, Alam M, Wallen NH, Nordlander R, Samad BA. CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol 2007; 120: 108-14.
27. Möllmann H, Schmidt-Schweda S, Nef H, et al. Contractile effects of angiotensin and endothelin in failing and non-failing human hearts. Int J Cardiol 2007; 114: 34-40.
28. Trachtenberg JD, Sun S, Choi ET, Callow AD, Ryan US. Effect of endothelin-1 infusion on the development of intimal hyperplasia after balloon catheter injury. J Cardiovasc Pharmacol 1993; 22 Suppl 8: S355-9.
29. Kirchengast M. Endothelin receptor blockade and in-stent restenosis. J Cardiovasc Pharmacol 2001; 38 Suppl 2: S31-4.
30. Kirchengast M, Münter K. Endothelin and restenosis. Cardiovasc Res 1998; 39: 550-5.
31. Garlichs CD, Zhang H, Mügge A, Daniel WG. Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur J Clin Invest 1999; 29: 12-6.
32. Kiowski W, Linder L, Erne P. Vascular effects of endothelin-1 in humans and influence of calcium channel blockade. J Hypertens Suppl 1994; 12: S21-6.
33. Talbodec A, Berkane N, Blandin V, et al. Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol 2000; 57: 797-804.
34. Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res 1998; 92: 83-9.